Our inaugural Editor-in-Chief is Julio Licinio, MD, PhD, MBA, MS, a prominent figure in the field of psychiatry and neuroscience, who has amassed a wealth of achievements and contributions to his field. Dr. Licinio is the author of 327 publications listed in Pubmed; his h-index is 90, and his work has been cited 42,166 times. His research has been competitively funded at the federal level for 25 years in two continents. As a testament to his eminence and broad achievements, he has been honored with prestigious titles such as Fellow of the Australian Academy of Health and Medical Sciences, Matthew Flinders Distinguished Professor at Flinders University, and State University of New York Distinguished Professor​​. His dedication to advancing medical education is evident through his leadership in graduate training programs in translational investigation, which have significantly benefited physician-scientists across multiple prestigious institutions including UCLA, the University of Miami, and the Australian National University. He was also Dean of the College of Medicine, State University of New York Upstate Medical University, where he is currently a Distinguished Professor.​

His pioneering work in the pharmacogenomics of antidepressants, where he has delved into the genetic underpinnings of individual responses to psychotropic medications, highlights his significant experience in psychopharmacology​​. This experience is further exemplified by his groundbreaking research on leptin’s role in obesity and its potential implications for appetite control, endocrinology, and the brain’s response to pharmacological interventions​​​. His body of scientific work showcases his forward-thinking in applying psychopharmacological research for therapeutic advancements​.

With over 30 years at the helm of academic publishing, Dr. Licinio has been instrumental in the founding and ascension of four journals, guiding them from their foundational stages to prominence and high-impact status. In a remarkable span of the last seven years, he has skillfully edited and brought to light 44 articles authored by nine Nobel Prize recipients, prominently featuring 19 works by the distinguished Paul Greengard. Dr. Licinio’s adept leadership was pivotal in elevating the first journal he created, transforming it from an emerging entity to the leading journal in its field worldwide in just over a decade.

Similarly, we are curating our Editorial Board from a list of eminent international experts. Our Board will epitomize diversity in expertise, geographical representation, gender, experience, and ethnicity. Confirmed members of the Editorial Board include:

Lucie Bartova, Medical University of Vienna, 1090 Vienna, Austria

Laura Bohn, The Herbert Wertheim University of Florida Scripps Institute for Biomedical Innovation and Technology, Jupiter, Florida 33458, USA

Robin Carhart-Harris, Weill Institute for Neurosciences, University of California, San Francisco, California 94158, USA

Alex K. Gearin, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR

Mark Geyer, University of California, San Diego, California 92093, USA

Gabriella Gobbi, McGill University, Montreal, Québec H3A 1A1, Canada

Javier González-Maeso, Virginia Commonwealth University, Richmond, Virginia 23298, USA

Steven Haggarty, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA

Emelie Katarina Svahn Leão, Federal University of Rio Grande do Norte (UFRN), Natal, RN 59078-970, Brazil

Bernard Lerer, Hadassah Medical Center, Hebrew University Jerusalem, Israel

Edythe London, University of California, Los Angeles, California 90095, USA

Charles Raison, University of Wisconsin-Madison, Madison, Wisconsin 53719, USA

Dusty Rose Miller, Vanderbilt University, Nashville, Tennessee 37212, USA

David E. Olson, University of California, Davis, California 95618, USA

Carol A. Paronis, Harvard Medical School and McLean Hospital, Belmont, Massachusetts 02478, USA

Jerrold F. Rosenbaum, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA

Stephanie Sillivan, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, USA

Michael A. Silver, University of California, Berkeley, California 94720, USA

1. Journal Overview

Psychedelics: The Journal of Psychedelic and Psychoactive Drug Research (Psychedelics) is a pioneering journal encompasses the broader landscape of psychoactive substances. We have a broad vision: to explore the full pharmacopeia of mind alteration, not just classical psychedelics. We examine not only serotonergic psychedelics, but also MDMA, ketamine, cannabinoids, stimulants, and plant-derived substances that resist easy categorization yet may hold significant therapeutic potential.

2. Aims & Scope

The principal aim of Psychedelics is to pioneer and consolidate the scientific understanding of psychedelic and psychoactive substances. Amidst a revolutionary surge in psychedelic research, we are committed to publishing high-caliber, rigorous research that explores the biological, clinical, psychological, and societal dimensions of these compounds. We intend to catalyze and shape the psychedelic renaissance by fostering international collaboration, bridging disciplinary divides, and influencing policy and practice with evidence-based findings.

Psychedelics holds a panoramic lens in a field as vast and multi-dimensional as psychedelic research. Our scope is comprehensive, encompassing the full spectrum of psychedelic and psychoactive inquiry. From molecular mechanisms to therapeutic applications, historical insights to societal implications, we provide a forum for diverse voices and perspectives. We invite submissions from all disciplines, embracing fundamental neuroscience, biochemistry, pharmacodynamics, clinical studies, brain imaging, therapeutic interventions, psychological explorations of perception and consciousness, and sociological examinations of historical usage and cultural impact.

Article Types

Psychedelics accepts 28 different article types to accommodate the full spectrum of psychedelic and psychoactive research and scholarship. From traditional original research articles and comprehensive reviews to innovative formats like data reports, study protocols, and multimedia presentations, we provide authors with the flexibility to choose the format that best suits their work. Complete descriptions of all article types and their requirements are available in our Author Instructions.

3. Open Access Statement

Psychedelics is a fully Open Access journal committed to the immediate, free dissemination of scientific knowledge.

We publish all content under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Articles published prior to June 17, 2025 were published under CC BY-NC-ND 4.0; however, all new submissions are published under the more permissive CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/deed.en). This means:

• Immediate free access: All articles are freely available to read, download, and share immediately upon publication
• No subscription barriers: No login requirements or paywalls restrict access to our content
• Reuse rights: Readers may copy, distribute, transmit, and adapt the work for any purpose, including commercial use, with proper attribution
• Author retention of copyright: Authors retain copyright of their work while granting the journal the right to publish
• Global accessibility: Our content is accessible worldwide without geographic or institutional barriers
• Machine readability: Full-text articles are available in formats suitable for text mining and computational analysis
• Permanent access: All published content remains freely accessible in perpetuity

This Open Access model ensures that research findings reach the widest possible audience, including researchers, clinicians, policymakers, patients, and the general public, thereby maximizing the impact and utility of published work.

Complete information about our Open Access policy is available at https://genomicpress.kglmeridian.com/view/journals/psychedelics/psychedelics-overview.xml?journal-tabs-desktop=About+this+Journal

4. Mission and Values

New insights into the mind and therapeutic potential of these remarkable compounds are being gained thanks to the psychedelic renaissance. As the first dedicated platform in this burgeoning field, the mission of Psychedelics is fourfold:

1. Promote Rigorous Research: Become a beacon for rigorous scientific exploration of psychedelic substances, welcoming experimental and observational studies, reviews, and meta-analyses that dissect psychedelics' biochemistry, pharmacodynamics, and therapeutic potential
2. Bridge Disciplinary Boundaries: Unite disparate disciplines by publishing cross-disciplinary research connecting molecular understanding with clinical, psychological, societal, and historical perspectives
3. Foster Collaboration: Build an international, collaborative community of researchers, clinicians, policymakers, and stakeholders to spark discourse and facilitate knowledge sharing
4. Influence Policy and Practice: Shape the psychedelic revolution through clear, evidence-based findings that influence medical, legal, and societal perspectives, leading to informed policy and practice

At the heart of Psychedelics reside our unwavering core values: academic integrity, scientific rigor, passionate purpose, relentless innovation, inclusive and cross-disciplinary team science, and excellence. We serve as a global platform celebrating the diverse tapestry of psychedelic research, welcoming contributions from every corner of the globe. Each manuscript is evaluated solely on its merit and potential contribution to the field, unswayed by geographical origin.

5. Research Impact and Visibility

Psychedelics publishes high-impact research that consistently receives exceptional attention from both the scientific community and global media. Our articles have been featured in major international news outlets, demonstrating their relevance and importance to global public health and scientific advancement.

Multiple publications in Psychedelics have achieved extraordinary recognition. Our breakthrough studies on therapeutic applications of psychedelics, novel compound discoveries, and clinical trial results have been covered by major outlets worldwide, including specialized medical and neuroscience news platforms. The research has been indexed across multiple academic search engines and databases, demonstrating its significant impact on the field.

This pattern of extensive media coverage and academic attention firmly establishes Psychedelics as an important international forum for disseminating critical developments in psychedelic research and mental health therapeutics. Our content demonstrates substantial real-world impact through extensive media coverage and influence on mental health policy and practice. This strong public engagement complements our commitment to publishing scientifically rigorous research from leading international researchers that addresses pressing questions in psychedelic science.

6. Article-Level Metrics and Impact Tracking (Altmetric)

Psychedelics provides comprehensive metrics for all published articles through our partnership with Altmetric, a leading provider of alternative metrics that track the online attention and engagement surrounding scholarly research.

Altmetric Integration

Every article published in Psychedelics receives an Altmetric badge that visually represents the online attention it has received. These distinctive, colorful "donuts" appear on all article pages and provide:

• Real-time tracking of mentions across diverse sources including news media, social media platforms, policy documents, patents, and scholarly blogs
• Detailed breakdowns showing where and how research is being discussed, shared, and used beyond traditional citations
• Geographic reach displaying the global distribution of attention to published research
• Attention scores that help authors, institutions, and readers quickly assess the broader impact and public engagement with research

This integration complements traditional citation metrics by capturing the immediate societal impact and public engagement with research published in Psychedelics, demonstrating how our articles contribute to public discourse, policy discussions, and knowledge dissemination beyond the academic community.

Authors can track their article's performance in real-time, and institutions can monitor the broader impact of their researchers' work, making Psychedelics an attractive venue for researchers seeking maximum visibility and engagement for their findings.

7. Governing Body and Editorial Structure

Psychedelics is guided by a distinguished Editorial Board comprising internationally recognized experts in psychedelic research, neuroscience, psychiatry, pharmacology, and related fields from prestigious institutions worldwide. Our Editorial Board represents a diverse array of perspectives and expertise essential to the multidisciplinary nature of psychedelic science.

The Editorial Board includes leading researchers from major universities and research institutions across North America, Europe, Asia, and Australia, ensuring comprehensive expertise across the entire spectrum of psychedelic and psychoactive research, from molecular pharmacology to clinical applications and public policy.

The exceptional caliber of our Editorial Board ensures comprehensive expertise across all areas of psychedelic science, from basic neuroscience to clinical psychiatry and public health. This global network of leading researchers helps Psychedelics attract high-quality submissions from around the world and provides expert peer review across all areas of psychedelic and psychoactive research.

The complete list of Editorial Board members and their affiliations is available at https://genomicpress.kglmeridian.com/view/journals/psychedelics/psychedelics-overview.xml?journal-tabs-desktop=Editorial+Board

8. Peer Review Process

Peer review stands as the foundational pillar of the scientific evaluation process, extensively employed in the assessment of research funding (grants) and research outcomes (papers). Our unwavering commitment resides in upholding the integrity of the editorial process, which rests upon an impartial peer review system.

Psychedelics adheres to the traditional single-blind peer review format, which is the most widely used. In this process, reviewers know the authors' identities, but authors do not know their reviewers' identities. This approach helps reviewers make informed assessments while protecting reviewer anonymity.

Every submission to Psychedelics, encompassing original research, reviews, correspondence, and all manuscript genres, will invariably undergo external evaluation via single-blind peer review. The only exception to the peer review process consists of purely informational material, such as news and editorials, which are explicitly identified as such.

Review Timeline

We are committed to providing timely peer review while maintaining rigorous standards. Authors can typically expect initial editorial decisions within 2-4 weeks of submission. This efficient review process ensures that important research reaches the scientific community promptly while maintaining the thoroughness necessary for high-quality peer review. The total average time from submission to publication is 45 days for Psychedelics.

To ensure the global diversity of Psychedelics, each submission is typically sent to eight experts, strategically selected to avoid concentration in any single country. Our editorial decisions aim to be grounded in at least three reviews, although if only two reviews are available, they will be considered in the decision-making process.

9. Publication Ethics and Scientific Integrity

At Psychedelics, scientific integrity is our cornerstone. We uphold the highest standards of scientific excellence through complete transparency and uncompromising honesty. As part of our commitment to publication ethics:

Ethical Guidelines

• All papers undergo rigorous peer review (see above)
• All submissions are screened for plagiarism of text, figures, and images
• We maintain clear policies regarding conflicts of interest, requiring disclosure from all authors, reviewers, and editors
• We follow ethical guidelines for research involving human subjects and animals
• We adhere to best practices for authorship attribution and credit

Complete information about our plagiarism screening policy is available at https://genomicpress.kglmeridian.com/view/journals/psychedelics/psychedelics-overview.xml?journal-tabs-desktop=About+this+Journal

Misconduct Investigation

We take potential misconduct seriously while recognizing the limitations of a journal's role in such matters. When concerns about potential misconduct arise, our approach is measured and procedural:

• Initial inquiries are directed to the corresponding author, seeking clarification on questioned issues
• If author explanations are insufficient or concerns persist, we may contact all co-authors to ensure awareness
• For unresolved concerns, we notify the authors' institution(s) so that a formal institutional inquiry can be conducted, as journals cannot compel authors to provide original data or conduct formal investigations
• We cooperate with institutional investigations while respecting their authority in addressing potential misconduct by their researchers

This balanced approach respects both the need for scientific integrity and the appropriate roles of journals versus research institutions in addressing misconduct concerns.

Publication Corrections

When correcting the published record, we take a contextual approach:

• Issuing errata for honest errors that do not impact overall conclusions
• Reserving retractions for cases involving misconduct, errors that undermine findings, extensive plagiarism, or overall loss of confidence in the work

While we largely align with the Committee on Publication Ethics (COPE) guidelines, we maintain flexibility to take different approaches when circumstances require. This may involve communicating with authors' institutions, funders, or other relevant oversight bodies to enable thorough investigations.

Appeals and Complaints Process

Authors who wish to appeal editorial decisions or lodge complaints about the peer review process should follow these procedures:

• Initial Appeal: Submit a detailed appeal letter to the Editor-in-Chief via support@genomicpress.com within 30 days of the decision, explaining why the decision should be reconsidered
• Review Process: Appeals are reviewed by the Editor-in-Chief, who may, at their discretion, consult with relevant Editorial Board members who were not involved in the original decision
• Timeline: Authors can expect a response to appeals within 2-3 weeks
• Final Decision: The Editor-in-Chief's decision on appeals is final
• Complaints: For complaints about editorial processes, ethics, or other concerns, contact support@genomicpress.com. All complaints are investigated thoroughly and addressed within 21 days

Data Sharing and Reproducibility Policy

To promote transparency and reproducibility in research:

• Data Availability Statement: All manuscripts must include a data availability statement describing where supporting data can be found
• Encouraged Practices: Authors are strongly encouraged to:
  • Deposit raw data in appropriate public repositories (e.g., GEO, dbGaP, Dryad, Figshare)
  • Share analysis code and scripts via GitHub or similar platforms
  • Provide detailed methods to enable replication
• Minimum Requirements: At minimum, authors must make available:
  • Data underlying all figures and tables
  • Custom code or algorithms essential to the conclusions
  • Detailed protocols for novel methods
• Exceptions: Restrictions may apply for patient privacy, proprietary data, or ethical constraints, which must be clearly stated
• Materials Sharing: Authors must agree to share unique materials (e.g., antibodies, cell lines, constructs) with qualified researchers upon reasonable request

Post-Publication Discussion Policy

We encourage scholarly discourse and maintain the integrity of the published record:

• Letters to the Editor: Readers may submit letters commenting on published articles within 6 months of publication
• Author Response: Original authors are invited to respond to substantive criticisms
• Post-Publication Review: We welcome post-publication peer review via established platforms (e.g., PubPeer)
• Social Media: Authors and readers are encouraged to discuss articles on social media using article DOIs

10. Publishing Schedule and Access

Print Edition

• ISSN: 2997-254X
• First Print Issue: January 2025
• Publication Frequency: Every two months

Online Edition

• ISSN: 2997-2671
• Early Online Release: Began January 2024
• Availability: Open Access
• Publication Type: Postpub

Psychedelics began with Early Online Release articles in January 2024, followed by our first formal print issue in January 2025. We have maintained our bi-monthly publication schedule with the January, March, and May 2025 issues already published and our July 2025 issue currently in production. Articles are made available online immediately upon final acceptance and production, with our content accessible through our dedicated website in an Open Access format.

11. Indexing Status and Publication Information

Psychedelics is registered with Crossref, providing all publications with searchable DOI links. Our DOI prefix is 10.61373.

The journal is indexed with the US Library of Congress, Scilit, and Google Scholar, ensuring our published research receives broad visibility in academic searches.

The journal has been assigned NLM ID 9919033202406676 and is listed in the NLM catalog, demonstrating our commitment to meeting MEDLINE standards.

PubMed Central Compliance

Psychedelics supports authors in meeting funder mandates for public access. While we are actively pursuing full MEDLINE/PubMed indexing, authors can currently deposit their accepted manuscripts in PubMed Central (PMC) to comply with NIH and other funding agency requirements. Successfully deposited manuscripts appear in PubMed with the designation "Author Manuscript" and receive PubMed IDs (PMIDs).

As a scholarly-driven publication, we are actively pursuing indexing in additional respected databases, including Medline/PubMed/Index Medicus, Scopus, Embase, and Clarivate (including Emerging Sources Citation Index, Journal Citation Reports and Web of Science). We are implementing an indexing strategy that will lead to inclusion in these platforms upon meeting their requirements, making prior submissions accessible retrospectively through those databases. We are taking all necessary measures to meet MEDLINE selection criteria and anticipate applying for full indexing in the near future.

12. Archiving and Long-term Preservation

Psychedelics is committed to ensuring permanent access to all published research through our partnership with Portico, a leading digital preservation service. We have recently deposited all our published issues with Portico, guaranteeing that our content will remain accessible to the scholarly community for generations to come.

About Portico

Portico is a community-supported digital preservation service that has been safeguarding scholarly content since 2005. As part of ITHAKA—a nonprofit organization dedicated to expanding access to knowledge and education worldwide—Portico serves as a trusted guardian of digital scholarship for over 1,000 publishers and 1,000 libraries globally.

Key features of Portico preservation:

• Certified Trustworthy Repository: Portico has been certified by the Center for Research Libraries as a Trustworthy Digital Repository, confirming that its practices meet the highest standards set by the preservation community
• Dark Archive Protection: Portico operates as a "dark archive," meaning content is preserved securely and made accessible if specific trigger events occur, ensuring uninterrupted access to research
• Triple Redundancy: Content is preserved in three geographically distributed locations for maximum security and protection against any form of data loss
• Format Migration: Portico continuously monitors and migrates content to new formats as technology evolves, ensuring your research remains accessible regardless of future technological changes
• Perpetual Access: Our partnership with Portico guarantees that all Psychedelics content will remain available to researchers, students, and scholars indefinitely, supporting the continuity of scientific knowledge

This comprehensive preservation strategy demonstrates our commitment to the long-term stewardship of the research we publish, ensuring that the important work appearing in Psychedelics will continue to contribute to scientific progress for decades to come.

Preprint Repository Archiving

In addition to our partnership with Portico for long-term preservation, Psychedelics supports authors' rights to archive their work in preprint repositories. Authors are free to archive their manuscripts in an institutional or other repository of their choice, such as medRxiv, bioRxiv, or similar repositories, at any stage of the publication process, supporting open science practices and early dissemination of research findings.

13. Copyright and Licensing Policies

Psychedelics maintains clear copyright and licensing policies that are accessible to all authors and readers. All published articles clearly indicate the copyright holder. As an Open Access journal, we publish content under a Creative Commons license, with specific terms clearly stated on each published article in both HTML and PDF formats.

Our website provides detailed author guidelines that include complete information about our copyright policies, licensing terms, and any requirements regarding the posting of final accepted versions or published articles on third-party repositories. Complete information about our copyright and licensing policies is available at https://genomicpress.kglmeridian.com/view/journals/psychedelics/psychedelics-overview.xml?journal-tabs-desktop=About+this+Journal

14. Author Fees and Revenue Sources

Psychedelics operates on an Article Processing Charge (APC) business model, with all revenue generated through these publication fees. Our APC structure provides the financial foundation for our high-quality peer review, production, and publication processes while maintaining our Open Access status.

Current APC Structure

From 1 May 2025 to 31 December 2025, Psychedelics offers promotional global APC rates: €1000/500 for submissions from within the European Union, £860/430 for those from the United Kingdom, CHF 1000/500 for those from Switzerland, JP¥170,000/85,000 for Japanese entries, and USD$990/495 for the United States and all other international submissions, with applicable local taxes. We will reassess our APC structure in 2026.

The academic and scholarly event announcements from non-profit organizations that appear in our journal are either provided at cost or offered free of charge as a service to the academic community. These announcements do not constitute a significant revenue source and are primarily included as a service to our readership.

15. Advertising Policy

Psychedelics maintains a restricted advertising policy that only accepts announcements from non-profit organizations for academic and scholarly events. We do not accept any commercial advertising. This selective approach ensures that any advertisements appearing on our website or in our publications are directly relevant to our academic audience and aligned with our scholarly mission. All such non-profit academic announcements are clearly distinguished from editorial content and are not related in any way to editorial decision-making. Our advertising policy is publicly available on our website to ensure complete transparency.

16. Ownership and Management

Psychedelics is published by Genomic Press, a specialized academic publisher focused on advancing open scientific communication in medicine and biosciences. Complete information about our ownership structure and management team is available on our website.

17. Contact Information

Editorial Office: Complete contact information for editorial inquiries is available on our website.

Author Guidelines: Detailed submission requirements, article type descriptions, and formatting instructions are available in our comprehensive Author Instructions.

Manuscript Submission: All manuscripts should be submitted through our online Submission Portal.

For general correspondence and additional information, please visit our website or contact our editorial office directly at support@genomicpress.com.

18. Direct Marketing Policy

Psychedelics maintains ethical standards in all marketing and solicitation activities:

• Targeted Communications: We only contact researchers whose work aligns with our journal's scope
• Opt-out Mechanism: All marketing communications include clear unsubscribe options
• No Spam: We do not engage in mass unsolicited emails or aggressive marketing tactics
• Transparency: All communications clearly identify Genomic Press and the specific journal
• Respect for Privacy: We do not share contact information with third parties
• Professional Standards: All marketing materials accurately represent our journal's scope, standards, and processes
• No Misleading Claims: We do not make exaggerated claims about impact factors, indexing, or publication timelines

Publishing with Psychedelics offers a distinct blend of benefits designed to champion your research and its impact. We guarantee a swift, meticulous, and personalized review process, ensuring your work is treated with the care and attention it deserves. Our commitment to global dissemination translates into a wide-reaching audience for your work, propelled further by our comprehensive press release strategy, providing worldwide access and visibility. In alignment with our dedication to equity and accessibility, we maintain a fair and transparent cost structure. our dedicated yet expansive focus on emerging research across multiple areas ensures your work will contribute to and thrive within the forefront of psychedelic science. Choose Psychedelics, where every piece of research is a step towards pioneering the future of psychedelic pharmacology and related sciences.

Amplifying Your Research Impact

In today's digital landscape, scientific communication extends far beyond traditional academic channels. At Psychedelics, we have developed a proven strategy that has generated over 500 news stories in more than 10 languages within our first two months of publication. Our comprehensive approach ensures your work achieves maximum visibility while maintaining rigorous scientific integrity.

Global Distribution Through EurekAlert!

All newsworthy articles published in Psychedelics are distributed through EurekAlert!, the world's leading science news service operated by AAAS. EurekAlert! has specific eligibility guidelines that news releases must meet to be accepted and hosted on their platform. Rest assured that Genomic Press will cover all submission fees associated with your press release. However, please note that payment of these fees does not guarantee acceptance by EurekAlert!

Psychedelics‘ recent success stories through EurekAlert! demonstrate the power of this approach:

• An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States: 88 media outlets across 10 languages  
• Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder: 80+ global media outlets

The extraordinary global media response to these publications in Psychedelics (Genomic Press) - with coverage spanning 88 media outlets across 10 languages - demonstrates not only the growing worldwide interest in psychedelic medicine but also establishes Psychedelics as a leading voice in this rapidly evolving field. This reach across major international media outlets, from Newsweek to China's healthcare press, reflects both the quality of research being published in Psychedelics and the journal's role as a key platform for communicating critical developments in mental health treatment innovation to a global scientific and medical audience.

Each newsworthy paper receives coverage through:

• EurekAlert! English language service (12,000+ journalists)
• Multiple language versions (Spanish, French, Chinese, Japanese, Arabic)
• Specialized scientific channels targeting specific research communities

Strategic Digital Dissemination

We leverage various social media platforms strategically:

• LinkedIn: Connect with industry leaders, potential collaborators, and research organizations
• X (formerly Twitter): Engage in real-time with the global scientific community
• Facebook: Reach broader academic audiences through established scientific groups
• Instagram: Transform complex concepts into visually engaging content
• YouTube: Share in-depth interviews and methodology explanations

Comprehensive Press Distribution

Beyond EurekAlert!, our press office maximizes impact through:

• International press release networks
• Specialized science media outlets
• Institutional press offices
• Scientific news services

The success of our approach is evident in the rapid global uptake of research published in Psychedelics. At Genomic Press, our goal is not simply to publicize your research, but to foster meaningful engagement within both academic circles and the broader scientific community, as demonstrated by our achievement of over 500 media stories across multiple languages in our first two months.